# Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment

Study · id `cardio:ct-nct01123980` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01123980](<https://clinicaltrials.gov/study/NCT01123980>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01123980

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 521 participants.

## Technical summary

Registry record NCT01123980. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-07-09.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 521 participants (enrolled count; ClinicalTrials.gov record NCT01123980, source copy `cardio:ctgov-nct01123980-2017-02-24`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01123980, source copy `cardio:ctgov-nct01123980-2017-02-24`, retrieved 2026-10-26)
- Primary completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01123980, source copy `cardio:ctgov-nct01123980-2017-02-24`, retrieved 2026-10-26)
- Completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01123980, source copy `cardio:ctgov-nct01123980-2017-02-24`, retrieved 2026-10-26)
- Results first posted: 2012-07-09 (ClinicalTrials.gov record NCT01123980, source copy `cardio:ctgov-nct01123980-2017-02-24`, retrieved 2026-10-26)
- Countries: China; Japan (ClinicalTrials.gov record NCT01123980, source copy `cardio:ctgov-nct01123980-2017-02-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01123980-2017-02-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
- Acronym: EasyMix
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): biphasic insulin aspart 30
- Intervention (Drug): metformin
- Intervention (Drug): glimepiride
- Intervention (Drug): insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes (`cardio:pubmed-23998560`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fa6f55cb60441d3b870632914ff75ab7ef92eae02cb91eb4cb6e247e797fdfff
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
